WallStSmart

BeiGene, Ltd. (ONC)vsCassava Sciences Inc (SAVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).

ONC

Hold

42

out of 100

Grade: D

Growth: 8.0Profit: 5.0Value: 3.0Quality: 6.5
Piotroski: 5/9Altman Z: 0.26

SAVA

Hold

36

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ONCSignificantly Overvalued (-1983.5%)

Margin of Safety

-1983.5%

Fair Value

$16.86

Current Price

$283.45

$266.59 premium

UndervaluedFair: $16.86Overvalued

Intrinsic value data unavailable for SAVA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ONC2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
32.8%10/10

Revenue surging 32.8% year-over-year

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

SAVA1 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Areas to Watch

ONC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
5.4%3/10

5.4% margin — thin

P/E RatioValuation
111.0x2/10

Premium valuation, high expectations priced in

SAVA4 concerns · Avg: 3.8/10
PEG RatioValuation
1.624/10

Expensive relative to growth rate

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$142.03M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.

Bull Case : SAVA

The strongest argument for SAVA centers on Price/Book.

Bear Case : ONC

The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.

Bear Case : SAVA

The primary concerns for SAVA are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

ONC profiles as a hypergrowth stock while SAVA is a value play — different risk/reward profiles.

ONC carries more volatility with a beta of 0.52 — expect wider price swings.

ONC is growing revenue faster at 32.8% — sustainability is the question.

ONC generates stronger free cash flow (131M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (42/100 vs 36/100) and 32.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Cassava Sciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Cassava Sciences, Inc., a clinical-stage biotechnology company, develops drugs for neurodegenerative diseases. The company is headquartered in Austin, Texas.

Want to dig deeper into these stocks?